학술논문

Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice
Document Type
Article
Source
Journal of Hepatology. Mar2009, Vol. 50 Issue 3, p562-571. 10p.
Subject
*EICOSAPENTAENOIC acid
*LIVER cancer
*LIVER diseases
*LIVER cells
*LABORATORY mice
*LIPID metabolism
*HEPATITIS
*OXYGEN in the body
*GENETICS
*THERAPEUTICS
Language
ISSN
0168-8278
Abstract
Background/Aims: Eicosapentaenoic acid (EPA) has been known as a reagent for improving lipid metabolism and inflammation. Hepatocyte-specific Pten-deficient mice exhibit hepatic lesions analogous to non-alcoholic steatohepatitis (NASH). Therefore, we administered EPA to Pten-deficient mice to investigate the mechanisms of NASH. Methods: Pten-deficient mice were assigned to a control group fed with a standard chow or an EPA group fed with a 5% EPA-supplemented standard chow. At 40weeks, livers from each group were processed to measure triglyceride content, gene expression analysis, Western blotting analysis, and histological examination. Level of serum reactive oxygen species (ROS) was also determined. Forty- and 76-week-old mice were used in tumor burden experiments. Results: EPA-ameliorated hepatic steatosis in Pten-deficient mice was based on decreased expression of AMPKα1-mediated SREBP-1c and increased PPARα expression. The EPA group exhibited less severe chronic hepatic inflammation compared to the control group, resulting from decreased ROS formation and a dramatically low ratio of arachidonic acid to EPA. Moreover, EPA inhibited development of hepatocellular carcinoma (HCC) in Pten-deficient mice based on an inhibition of MAPK activity and a low ratio of oleic to stealic acid, and a reduction in ROS formation. Conclusions: EPA ameliorated steatohepatitis and development of HCC in Pten-deficient mice. [Copyright &y& Elsevier]